EGFR (ErbB1) and ErbB2 receptors stimulate several intracellular signaling pathways in non-
small-cell lung cancer (NSCLC). Adenocarcinomas (AC) and squamous cell carcinomas …

Introduction. Epidermal growth factor receptor (EGFR) mutations are known as oncogene
driver mutations and with EGFR mutations exhibit good response to the EGFR tyrosine …

Background: The human epidermal growth factor receptors HER1/EGFR and HER2 offer
potential targets for treating non-small cell lung cancer (NSCLC). The antitumor efficacy of …

A signaling pathway that is frequently deregulated in human carcinomas and has been
explored as a therapeutic target involves the activation of the epidermal growth factor …

G-protein-coupled estrogen receptor (GPER) was found to promote non-small cell lung
cancer (NSCLC) by estrogen, indicating the potential necessity of inhibiting GPER by a …

Increasing evidence indicates that estrogen promotes tumor growth in both estrogen target
organs and non-target organs. Estrogen regulates cell proliferation and differentiation via …

Background: Expression of estrogen receptor beta (ERβ) is a potentially interesting
prognostic marker and therapeutic target in non-small cell lung cancer (NSCLC). Although …

Patients with non-small cell lung cancer (NSCLC) who have activating epidermal growth
factor receptor (EGFR) mutations benefit from treatment with EGFR-tyrosine kinase inhibitors …

As 20% of stage I NSCLC patients develop recurrent and often incurable cancer, the
identification of prognostic markers has a meaningful clinical application. The biological …

Objective To investigate the expression and clinicopathological significance of the
oestrogen receptor (ER) in non-small cell lung cancer (NSCLC). Methods ER expression …